Download PDF
Semin Reprod Med 2010; 28(6): 506-512
DOI: 10.1055/s-0030-1265678
© Thieme Medical Publishers

Ovarian Hyperstimulation Syndrome Prevention Strategies: Luteal Support Strategies to Optimize Pregnancy Success in Cycles with Gonadotropin-Releasing Hormone Agonist Ovulatory Trigger

Lawrence Engmann1 , Claudio Benadiva1
  • 1Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, University of Connecticut Health Center, Farmington, Connecticut
Further Information

Publication History

Publication Date:
16 November 2010 (online)

    Permissions and Reprints

ABSTRACT

Gonadotropin-releasing hormone agonist(GnRHa) administration for the induction of oocyte maturation during in vitro fertilization treatment is effective in the prevention of ovarian hyperstimulation syndrome (OHSS). However, some studies have reported a lower ongoing pregnancy rate after GnRHa trigger. The excellent conception rates reported in recipients receiving embryos originating from donor cycles or in women receiving frozen embryos originating from fresh cycles during which GnRHa was used to induce oocyte maturation suggest that it does not adversely affect the quality of the oocyte or embryo. A defective corpus luteum function resulting from the relatively short endogenous luteinizing hormone surge may be detrimental to endometrial receptivity. Aggressive luteal phase support and monitoring is therefore essential in view of the overwhelming evidence suggestive of abnormal luteal phase steroid profile. This may be achieved by the use of adequate estradiol and progesterone supplementation in the luteal phase and the first trimester. An alternative approach is the use of adjuvant low-dose human chorionic gonadotropin, although caution should be exercised in view of the associated risk of OHSS development.

KEYWORDS

GnRH agonist trigger - luteal phase support - OHSS

REFERENCES

  • 1 Itskovitz-Eldor J, Kol S, Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication.  Hum Reprod. 2000;  15(9) 1965-1968
    CrossrefPubMedGoogle Scholar
  • 2 De Jong D, Van Hooren E G, Macklon N S, Mannaerts B M, Fauser B C. Pregnancy and birth after GnRH agonist treatment for induction of final oocyte maturation in a woman undergoing ovarian stimulation for ICSI, using a GnRH antagonist (Orgalutran/Antagon) to prevent a premature LH surge: a case report.  J Assist Reprod Genet. 2001;  18(1) 30-33
    CrossrefPubMedGoogle Scholar
  • 3 Acevedo B, Gomez-Palomares J L, Ricciarelli E, Hernández E R. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates.  Fertil Steril. 2006;  86(6) 1682-1687
    CrossrefPubMedGoogle Scholar
  • 4 Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.  Fertil Steril. 2008;  89(1) 84-91
    CrossrefPubMedGoogle Scholar
  • 5 DiLuigi A J, Engmann L, Schmidt D W, Maier D B, Nulsen J C, Benadiva C A. GnRH agonist to induce final oocyte maturation prevents the development of ovarian hyperstimulation syndrome (OHSS) in high-risk patients and leads to improved clinical outcomes compared with coasting.  Fertil Steril. 2010;  , January 12 (Epub ahead of print)
    PubMedGoogle Scholar
  • 6 Cerrillo M, Rodríguez S, Mayoral M, Pacheco A, Martínez-Salazar J, Garcia-Velasco J A. Differential regulation of VEGF after final oocyte maturation with GnRH agonist versus hCG: a rationale for OHSS reduction.  Fertil Steril. 2009;  91(4, Suppl) 1526-1528
    CrossrefPubMedGoogle Scholar
  • 7 Kol S. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome.  Fertil Steril. 2004;  81(1) 1-5
    PubMedGoogle Scholar
  • 8 Hillensjö T, LeMaire W J. Gonadotropin releasing hormone agonists stimulate meiotic maturation of follicle-enclosed rat oocytes in vitro.  Nature. 1980;  287(5778) 145-146
    CrossrefPubMedGoogle Scholar
  • 9 Ekholm C, Hillensjö T, Isaksson O. Gonadotropin releasing hormone agonists stimulate oocyte meiosis and ovulation in hypophysectomized rats.  Endocrinology. 1981;  108(5) 2022-2024
    CrossrefPubMedGoogle Scholar
  • 10 Yoshimura Y, Nakamura Y, Oda T et al. Effects of gonadotropin-releasing hormone agonists on meiotic maturation of follicle-enclosed oocytes in rabbits.  Biol Reprod. 1990;  43(6) 1012-1018
    CrossrefPubMedGoogle Scholar
  • 11 Fauser B C, de Jong D, Olivennes F et al. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization.  J Clin Endocrinol Metab. 2002;  87(2) 709-715
    CrossrefPubMedGoogle Scholar
  • 12 Beckers N G, Macklon N S, Eijkemans M J et al. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.  J Clin Endocrinol Metab. 2003;  88(9) 4186-4192
    CrossrefPubMedGoogle Scholar
  • 13 Nevo O, Eldar-Geva T, Kol S, Itskovitz-Eldor J. Lower levels of inhibin A and pro-alphaC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human chorionic gonadotropin.  Fertil Steril. 2003;  79(5) 1123-1128
    CrossrefPubMedGoogle Scholar
  • 14 Engmann L, Siano L, Schmidt D, Nulsen J, Maier D, Benadiva C. GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS.  Reprod Biomed Online. 2006;  13(5) 639-644
    CrossrefPubMedGoogle Scholar
  • 15 Babayof R, Margalioth E J, Huleihel M et al. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.  Hum Reprod. 2006;  21(5) 1260-1265
    CrossrefPubMedGoogle Scholar
  • 16 Humaidan P, Bredkjaer H E, Bungum L et al. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.  Hum Reprod. 2005;  20(5) 1213-1220
    CrossrefPubMedGoogle Scholar
  • 17 Kolibianakis E M, Schultze-Mosgau A, Schroer A et al. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists.  Hum Reprod. 2005;  20(10) 2887-2892
    CrossrefPubMedGoogle Scholar
  • 18 Henzl M R. Gonadotropin-releasing hormone and its analogues: from laboratory to bedside.  Clin Obstet Gynecol. 1993;  36 617-635
    CrossrefPubMedGoogle Scholar
  • 19 Melo M, Busso C E, Bellver J et al. GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study.  Reprod Biomed Online. 2009;  19(4) 486-492
    CrossrefPubMedGoogle Scholar
  • 20 Bodri D, Guillén J J, Galindo A, Mataró D, Pujol A, Coll O. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.  Fertil Steril. 2009;  91(2) 365-371
    CrossrefPubMedGoogle Scholar
  • 21 Griesinger G, Kolibianakis E M, Papanikolaou E G et al. Triggering of final oocyte maturation with gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles.  Fertil Steril. 2007;  88(3) 616-621
    CrossrefPubMedGoogle Scholar
  • 22 Eldar-Geva T, Zylber-Haran E, Babayof R et al. Similar outcome for cryopreserved embryo transfer following GnRH-antagonist/GnRH-agonist, GnRH-antagonist/HCG or long protocol ovarian stimulation.  Reprod Biomed Online. 2007;  14(2) 148-154
    CrossrefPubMedGoogle Scholar
  • 23 Chandrasekher Y A, Hutchison J S, Zelinski-Wooten M B, Hess D L, Wolf D P, Stouffer R L. Initiation of periovulatory events in primate follicles using recombinant and native human luteinizing hormone to mimic the midcycle gonadotropin surge.  J Clin Endocrinol Metab. 1994;  79(1) 298-306
    CrossrefPubMedGoogle Scholar
  • 24 Cheng C K, Leung P C. Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans.  Endocr Rev. 2005;  26(2) 283-306
    CrossrefPubMedGoogle Scholar
  • 25 Tesarik J, Hazout A, Mendoza C. Enhancement of embryo developmental potential by a single administration of GnRH agonist at the time of implantation.  Hum Reprod. 2004;  19(5) 1176-1180
    CrossrefPubMedGoogle Scholar
  • 26 Isik A Z, Caglar G S, Sozen E et al. Single-dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study.  Reprod Biomed Online. 2009;  19(4) 472-477
    CrossrefPubMedGoogle Scholar
  • 27 Sismanoglu A, Tekin H I, Erden H F, Ciray N H, Ulug U, Bahçeci M. Ovulation triggering with GnRH agonist vs. hCG in the same egg donor population undergoing donor oocyte cycles with GnRH antagonist: a prospective randomized cross-over trial.  J Assist Reprod Genet. 2009;  26(5) 251-256
    CrossrefPubMedGoogle Scholar
  • 28 Galindo A, Bodri D, Guillén J J, Colodrón M, Vernaeve V, Coll O. Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial.  Gynecol Endocrinol. 2009;  25(1) 60-66
    CrossrefPubMedGoogle Scholar
  • 29 Shapiro B S, Daneshmand S T, Garner F C, Aguirre M, Ross R. Comparison of human chorionic gonadotropin and gonadotropin-releasing hormone agonist for final oocyte maturation in oocyte donor cycles.  Fertil Steril. 2007;  88(1) 237-239
    CrossrefPubMedGoogle Scholar
  • 30 Hernández E R, Gómez-Palomares J L, Ricciarelli E. No room for cancellation, coasting, or ovarian hyperstimulation syndrome in oocyte donation cycles.  Fertil Steril. 2009;  91(4, Suppl) 1358-1361
    CrossrefPubMedGoogle Scholar
  • 31 Penzias A S. Luteal phase support.  Fertil Steril. 2002;  77(2) 318-323
    CrossrefPubMedGoogle Scholar
  • 32 Pritts E A, Atwood A K. Luteal phase support in infertility treatment: a meta-analysis of the randomized trials.  Hum Reprod. 2002;  17(9) 2287-2299
    CrossrefPubMedGoogle Scholar
  • 33 Daya S, Gunby J. Luteal phase support in assisted reproduction cycles.  Cochrane Database Syst Rev. 2004;  (3) CD004830
    PubMedGoogle Scholar
  • 34 Engmann L, DiLuigi A, Schmidt D, Benadiva C, Maier D, Nulsen J. The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study.  Fertil Steril. 2008;  89(3) 554-561
    CrossrefPubMedGoogle Scholar
  • 35 Jee B C, Suh C S, Kim S H, Kim Y B, Moon S Y. Effects of estradiol supplementation during the luteal phase of in vitro fertilization cycles: a meta-analysis.  Fertil Steril. 2010;  93(2) 428-436
    CrossrefPubMedGoogle Scholar
  • 36 Shapiro B S, Daneshmand S T, Garner F C, Aguirre M, Thomas S. Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization.  Fertil Steril. 2008;  90(1) 231-233
    CrossrefPubMedGoogle Scholar
  • 37 Humaidan P, Bungum L, Bungum M, Yding Andersen C. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study.  Reprod Biomed Online. 2006;  13(2) 173-178
    CrossrefPubMedGoogle Scholar
  • 38 Humaidan P. Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study.  Reprod Biomed Online. 2009;  18(5) 630-634
    CrossrefPubMedGoogle Scholar
  • 39 Humaidan P, Ejdrup Bredkjaer H, Westergaard L G, Yding Andersen C. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.  Fertil Steril. 2010;  93(3) 847-854
    CrossrefPubMedGoogle Scholar
  • 40 Castillo J C, Dolz M, Bienvenido E, Abad L, Casañ E M, Bonilla-Musoles F. Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal support.  Reprod Biomed Online. 2010;  20(2) 175-181
    CrossrefPubMedGoogle Scholar

Lawrence EngmannM.D. M.R.C.O.G. 

The Center for Advanced Reproductive Services, University of Connecticut Health Center, Dowling South Building

263 Farmington Avenue, Farmington, CT 06030-6224

Email: lengmann@uchc.edu

      >